345 related articles for article (PubMed ID: 30788290)
1. On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy.
Kong BY; Bolton H; Kim JW; Silveira PA; Fromm PD; Clark GJ
Front Oncol; 2019; 9():50. PubMed ID: 30788290
[TBL] [Abstract][Full Text] [Related]
2. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
3. Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.
Carenza C; Calcaterra F; Oriolo F; Di Vito C; Ubezio M; Della Porta MG; Mavilio D; Della Bella S
Front Immunol; 2019; 10():1325. PubMed ID: 31244860
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside.
Ghorbaninezhad F; Asadzadeh Z; Masoumi J; Mokhtarzadeh A; Kazemi T; Aghebati-Maleki L; Shotorbani SS; Shadbad MA; Baghbanzadeh A; Hemmat N; Bakhshivand M; Baradaran B
Life Sci; 2022 May; 297():120466. PubMed ID: 35271882
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
6. Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy.
Corogeanu D; Diebold SS
Clin Exp Immunol; 2022 Jul; 209(1):64-71. PubMed ID: 35352109
[TBL] [Abstract][Full Text] [Related]
7. [Immune checkpoint inhibitors. A breakthrough in cancer therapy].
Cárdenas-Oyarzo AM; Bocchieri-Oyarce PA; Méndez-Laport CR; Zolezzi JM; Ríos JA
Rev Med Chil; 2022 Jan; 150(1):93-99. PubMed ID: 35856970
[TBL] [Abstract][Full Text] [Related]
8. Not All Immune Checkpoints Are Created Equal.
De Sousa Linhares A; Leitner J; Grabmeier-Pfistershammer K; Steinberger P
Front Immunol; 2018; 9():1909. PubMed ID: 30233564
[TBL] [Abstract][Full Text] [Related]
9. Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4
Beavis PA; Henderson MA; Giuffrida L; Davenport AJ; Petley EV; House IG; Lai J; Sek K; Milenkovski N; John LB; Mardiana S; Slaney CY; Trapani JA; Loi S; Kershaw MH; Haynes NM; Darcy PK
Cancer Immunol Res; 2018 Sep; 6(9):1069-1081. PubMed ID: 30018045
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Rotte A; Jin JY; Lemaire V
Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
[TBL] [Abstract][Full Text] [Related]
11. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin MM; Zhang X; Schuster H; Caron E; Ward JP; Noguchi T; Ivanova Y; Hundal J; Arthur CD; Krebber WJ; Mulder GE; Toebes M; Vesely MD; Lam SS; Korman AJ; Allison JP; Freeman GJ; Sharpe AH; Pearce EL; Schumacher TN; Aebersold R; Rammensee HG; Melief CJ; Mardis ER; Gillanders WE; Artyomov MN; Schreiber RD
Nature; 2014 Nov; 515(7528):577-81. PubMed ID: 25428507
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.
Stecher C; Battin C; Leitner J; Zettl M; Grabmeier-Pfistershammer K; Höller C; Zlabinger GJ; Steinberger P
Front Immunol; 2017; 8():572. PubMed ID: 28588576
[TBL] [Abstract][Full Text] [Related]
14. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
15. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors win the 2018 Nobel Prize.
Huang PW; Chang JW
Biomed J; 2019 Oct; 42(5):299-306. PubMed ID: 31783990
[TBL] [Abstract][Full Text] [Related]
17. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
18. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy.
Datta J; Berk E; Cintolo JA; Xu S; Roses RE; Czerniecki BJ
Front Immunol; 2015; 6():271. PubMed ID: 26082780
[TBL] [Abstract][Full Text] [Related]
19. Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment.
Belderbos RA; Aerts JGJV; Vroman H
Mol Ther Oncolytics; 2019 Jun; 13():67-81. PubMed ID: 31020037
[TBL] [Abstract][Full Text] [Related]
20. The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants.
Ding J; Zheng Y; Wang G; Zheng J; Chai D
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188763. PubMed ID: 35872287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
